Immatics (NASDAQ:IMTXW) Short Interest Update

Immatics (NASDAQ:IMTXW) was the recipient of a large increase in short interest in the month of September. As of September 15th, there was short interest totalling 1,500 shares, an increase of 7.1% from the August 31st total of 1,400 shares. Based on an average daily trading volume, of 1,200 shares, the short-interest ratio is currently 1.3 days.

Immatics Price Performance

Immatics stock opened at $2.16 on Wednesday. The company’s 50 day simple moving average is $2.64 and its 200-day simple moving average is $2.79. Immatics has a 1 year low of $1.60 and a 1 year high of $4.14.

About Immatics

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.